MyMD Pharmaceuticals Inc (MYMD)
2.23
+0.13
(+6.19%)
USD |
NASDAQ |
May 16, 16:00
2.23
0.00 (0.00%)
After-Hours: 20:00
MyMD Pharmaceuticals Enterprise Value: -0.2476M for May 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 15, 2024 | -0.2476M |
| May 14, 2024 | 0.2486M |
| May 13, 2024 | 0.6389M |
| May 10, 2024 | 0.6154M |
| May 09, 2024 | 0.6801M |
| May 08, 2024 | 1.112M |
| May 07, 2024 | 1.090M |
| May 06, 2024 | 1.824M |
| May 03, 2024 | 2.406M |
| May 02, 2024 | 2.234M |
| May 01, 2024 | 2.126M |
| April 30, 2024 | 1.867M |
| April 29, 2024 | 1.478M |
| April 26, 2024 | 1.349M |
| April 25, 2024 | 1.284M |
| April 24, 2024 | 1.392M |
| April 23, 2024 | 0.7449M |
| April 22, 2024 | 0.788M |
| April 19, 2024 | 0.6154M |
| April 18, 2024 | 0.6583M |
| April 17, 2024 | 0.076M |
| April 16, 2024 | -0.2476M |
| April 15, 2024 | 0.1192M |
| April 12, 2024 | 0.3996M |
| April 11, 2024 | 0.6154M |
| Date | Value |
|---|---|
| April 10, 2024 | 1.155M |
| April 09, 2024 | 0.8743M |
| April 08, 2024 | 0.7664M |
| April 05, 2024 | -0.2476M |
| April 04, 2024 | -0.0746M |
| April 03, 2024 | 0.076M |
| April 02, 2024 | 0.0113M |
| April 01, 2024 | 0.1192M |
| March 28, 2024 | 0.2203M |
| March 27, 2024 | 0.1367M |
| March 26, 2024 | 0.053M |
| March 25, 2024 | 0.3667M |
| March 22, 2024 | 0.7641M |
| March 21, 2024 | 1.224M |
| March 20, 2024 | 1.203M |
| March 19, 2024 | 1.245M |
| March 18, 2024 | 1.162M |
| March 15, 2024 | 1.245M |
| March 14, 2024 | 1.705M |
| March 13, 2024 | 1.956M |
| March 12, 2024 | 1.810M |
| March 11, 2024 | 2.605M |
| March 08, 2024 | 1.894M |
| March 07, 2024 | 1.831M |
| March 06, 2024 | 1.622M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-0.2476M
Minimum
Apr 05 2024
347.36M
Maximum
Nov 01 2021
99.36M
Average
81.36M
Median
Jan 30 2023
Enterprise Value Benchmarks
| Acrivon Therapeutics Inc | 157.10M |
| Vincerx Pharma Inc | 3.233M |
| CEL-SCI Corp | 74.49M |
| AIM ImmunoTech Inc | 7.560M |
| IGC Pharma Inc | 35.28M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.364M |
| Total Expenses (Quarterly) | 4.908M |
| EPS Diluted (Quarterly) | -2.93 |
| Earnings Yield | -252.5% |